Immunosuppressive therapy of patients with pemphigus with ineffectiveness of systemic corticosteroids
- Authors: Chikin V.V.1, Karamova A.E.1
-
Affiliations:
- State Research Center of Dermatovenereology and Cosmetology
- Issue: Vol 100, No 6 (2024)
- Pages: 6-21
- Section: REVIEWS
- URL: https://journals.rcsi.science/0042-4609/article/view/279229
- DOI: https://doi.org/10.25208/vdv16808
- ID: 279229
Cite item
Full Text
Abstract
Therapy of patients with pemphigus vulgaris with systemic corticosteroids may not be effective enough or lead to the development of severe adverse events that make it necessary to reduce the dose of corticosteroid. In such cases, it is possible to use the immunosuppressants. The literature review analyzes case reports and the results of studies that evaluated the effectiveness and safety of drugs used for immunosuppressive therapy of patients with pemphigus vulgaris. The drugs doses, the studies design, and criteria for evaluating the effectiveness of therapy in patients with pemphigus are considered. As a result of the analysis, it was shown that case reports and non-compatarive studies demonstrate the effectiveness and steroid-sparing effect of azathioprine, dapsone, methotrexate, mycophenolate mofetil, cyclosporine and cyclophosphamide in the treatment of patients with pemphigus vulgaris. Nevertheless, comparative studies show an increase in the effectiveness of therapy in patients with pemphigus and a faster achievement of therapeutic effect when prescribing cyclophosphamide, but not azathioprine, dapsone, methotrexate, mycophenolate mofetil or cyclosporine. However, the toxicity of cyclophosphamide limits its use in pemphigus. Thus, adjuvant drugs can be used in the treatment of patients with pemphigus in situations where it is not possible to reduce the dose of a systemic corticosteroid, especially in cases of severe adverse events of corticosteroid therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Vadim V. Chikin
State Research Center of Dermatovenereology and Cosmetology
Author for correspondence.
Email: chikin@cnikvi.ru
ORCID iD: 0000-0002-9688-2727
SPIN-code: 3385-4723
MD, Dr. Sci. (Med.), Senior Researcher
Russian Federation, 3 bldg 6 Korolenko street, 107076 MoscowArfenya E. Karamova
State Research Center of Dermatovenereology and Cosmetology
Email: karamova@cnikvi.ru
ORCID iD: 0000-0003-3805-8489
SPIN-code: 3604-6491
MD, Dr. Sci. (Med.), Senior Researcher
Russian Federation, 3 bldg 6 Korolenko street, 107076 MoscowReferences
- Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132(2):203–212. doi: 10.1001/archderm.1996.03890260105016
- Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113(9):1236–1241. doi: 10.1001/archderm.1977.01640090084013
- Feliciani C, Cozzani E, Marzano AV, Caproni M, Di Zenzo G, Calzavara-Pinton P, et al. Italian Guidelines in Pemphigus — adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV). G Ital Dermatol Venereol. 2018;153(5):599–608. doi: 10.23736/S0392-0488.18.06073-X
- Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913. doi: 10.1111/jdv.16752
- Murrell DF, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575–585. e1. doi: 10.1016/j.jaad.2018.02.021
- Chu CY, Lee CH, Lee HE, Cho YT, Hsu CK, Chan TC, et al. Taiwanese dermatological association (TDA) consensus for the management of pemphigus. J Formos Med Assoc. 2023;122(7):540–548. doi: 10.1016/j.jfma.2022.12.005
- Harris E, Tiganescu A, Tubeuf S, Mackie SL. The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. Curr Rheumatol Rep. 2015;17(6):513. doi: 10.1007/s11926-015-0513-4
- Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clin Ther. 2017;39(11):2216–2229. doi: 10.1016/j.clinthera.2017.09.011
- Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376–383. doi: 10.1016/j.atherosclerosis.2006.05.019
- Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153(11):1089–1093. doi: 10.1093/aje/153.11.1089
- Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–1124. doi: 10.1136/ard.2008.092163
- Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–963. doi: 10.1093/clinids/11.6.954
- Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55(1):19–26. doi: 10.1002/art.21705
- De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208–214. doi: 10.1002/art.22294
- Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–1432. doi: 10.1016/j.clinthera.2011.09.009
- Kumar S, De D, Handa S, Ratho RK, Bhandari S, Pal A, et al. Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris. Br J Dermatol. 2017;177(6):1583–1589. doi: 10.1111/bjd.15658
- Davarmanesh M, Zahed M, Sookhakian A, Jehbez S. Oral pemphigus vulgaris treatment with corticosteroids and azathioprine: A long-term study in Shiraz, Iran. Evid Based Complement Alternat Med. 2022;2022:7583691. doi: 10.1155/2022/7583691
- Azizi A, Lawaf S. The management of oral pemphigus vulgaris with systemic corticosteroid and dapsone. J Dent Res Dent Clin Dent Prospects. 2008;2(1):33–37. doi: 10.5681/joddd.2008.007
- Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, et al. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):264–271. doi: 10.1016/j.jaad.2015.04.038
- Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid — a 4 year follow-up. Br J Dermatol. 1974;91(1):103–109. doi: 10.1111/j.1365-2133.1974.tb06725.x
- van Dijk TJ, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica. 1973;147(3):179–185. doi: 10.1159/000251868
- Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol. 1987;16(3 Pt 1):527–533. doi: 10.1016/s0190-9622(87)70069-3
- Rose E, Wever S, Zilliken D, Linse R, Haustein UF, Bröcker EB. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges. 2005;3(3):200–206. doi: 10.1111/j.1610-0378.2005.04747.x
- Sukanjanapong S, Thongtan D, Kanokrungsee S, Suchonwanit P, Chanprapaph K. A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with pemphigus: A retrospective cohort study. Dermatol Ther (Heidelb). 2020;10(1):179–189. doi: 10.1007/s13555-019-00346-x
- Chaidemenos G, Apalla Z, Koussidou T, Papagarifallou I, Ioannides D. High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study. J Eur Acad Dermatol Venereol. 2011;25(2):206–210. doi: 10.1111/j.1468-3083.2010.03753.x
- Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8(2):85–92. doi: 10.2165/00128071-200708020-00004
- Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622–628. doi: 10.1016/j.jaad.2007.05.024
- Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, Davatchi F, Balighi K, Esmaili N, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(10):1285–1292. doi: 10.1111/j.1468-3083.2012.04717.x
- Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976;94(6):681–686. doi: 10.1111/j.1365-2133.1976.tb05168.x
- Quaresma MV, Bernardes Filho F, Hezel J, Peretti MC, Kac BK, Azulay-Abulafia L. Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent. An Bras Dermatol. 2015;90(3 Suppl 1):51–54. doi: 10.1590/abd1806-4841.20153408
- Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica. 1978;156(2):120–123. doi: 10.1159/000250907
- Tan HH, Tay YK. An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers. Clin Exp Dermatol. 2000;25(3):224–226. doi: 10.1046/j.1365-2230.2000.00622.x
- Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005;141(6):699–702. doi: 10.1001/archderm.141.6.699
- Werth VP, Fivenson D, Pandya AG, Chen D, Rico MJ, Albrecht J, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25–32. doi: 10.1001/archderm.144.1.25
- Baum S, Greenberger S, Samuelov L, Solomon M, Lyakhovitsky A, Trau H, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22(1):83–87. doi: 10.1684/ejd.2011.1611
- Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol. 1988;68(5):413–421.
- Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135(10):1275–1276. doi: 10.1001/archderm.135.10.1275
- Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol. 1970;83(2):315–323. doi: 10.1111/j.1365-2133.1970.tb15707.x
- Piamphongsant T, Sivayathorn A. Pemphigus: combined treatment with methotrexate and prednisone. J Med Assoc Thai. 1975;58(3):171–176.
- Jain K, Thakur V, Handa S, Thakur N, Shilpa, Sachdeva N, et al. A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris. Sci Rep. 2022;12(1):7525. doi: 10.1038/s41598-022-11387-2
- Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169(4):916–921. doi: 10.1111/bjd.12474
- Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol. 1972;106(4):491–497. doi: 10.1001/archderm.1972.01620130023006
- Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161(4):723–731. doi: 10.1111/j.1365-2133.2009.09246.x
- Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40(2 Pt 1):265–268. doi: 10.1016/s0190-9622(99)70203-3
- Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135(1):54–56. doi: 10.1001/archderm.135.1.54
- Powell AM, Albert S, Al Fares S, Harman KE, Setterfield J, Bhogal B, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149(1):138–145. doi: 10.1046/j.1365-2133.2003.05269.x
- Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139(6):739–742. doi: 10.1001/archderm.139.6.739
- Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447–1454. doi: 10.1001/archderm.142.11.1447
- Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. 2012;26(7):855–860. doi: 10.1111/j.1468-3083.2011.04170.x
- Doukaki S, Platamone A, Alaimo R, Bongiorno MR. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Dermatolog Treat. 2015;26(1):67–72. doi: 10.3109/09546634.2014.880395
- Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol. 1994;30(5 Pt 1):752–757. doi: 10.1016/s0190-9622(08)81506-x
- Barthelemy H, Frappaz A, Cambazard F, Mauduit G, Rouchouse B, Kanitakis J, et al. Treatment of nine cases of pemphigus vulgaris with cyclosporine. J Am Acad Dermatol. 1988;18(6):1262–1266. doi: 10.1016/s0190-9622(88)70132-2
- Alijotas J, Pedragosa R, Bosch J, Vilardell M. Prolonged remission after cyclosporine therapy in pemphigus vulgaris: report of two young siblings. J Am Acad Dermatol. 1990;23(4 Pt 1):701–703. doi: 10.1016/0190-9622(90)70277-o
- Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol. 2000;136(7):868–872. doi: 10.1001/archderm.136.7.868
- Bondesson L, Hammar H. Treatment of pemphigus vulgaris with cyclosporine. Dermatologica. 1990;181(4):308–310. doi: 10.1159/000247834
- Матушевская Е.В., Свирщевская Е.В., Кубанова А.А., Самсонов В.А., Хапилова В.И. Изучение фенотипа и функций Т-клеток больных вульгарной пузырчаткой при лечении сандимуном и глюкокортикоидами. Вестник дерматологии и венерологии. 1995;5:6–11. [Matushevskaya EV, Svirschchevskaya EV, Kubanova AA, Samsonov VA, Khapilova VI. Investigation of phenotype and T-cells functions in pemphigus vulgaris patients treated with sandimmun and glucocorticoides. Vestnik Dermatologii i Venerologii. 1995;5:6–11. (In Russ.)]
- Кубанова А.А., Самсонов В.А., Хапилова В.И., Матушевская Е.В. Сандиммун в терапии больных истинной пузырчаткой. Вестник дерматологии и венерологии. 1994;6:42. [Kubanova AA, Samsonov VA, Khapilova VI, Matushevskaya EV. Sandimmun v terapii bol’nykh istinnoy puzyrchatkoy. Vestnik Dermatologii i Venerologii. 1994;6:42. (In Russ.)]
- Ebringer A, Mackay IR. Pemphigus vulgaris successfully treated with cyclophosphamide. Ann Intern Med. 1969;71(1):125–127. doi: 10.7326/0003-4819-71-1-125
- Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol. 1972;106(5):657–661. doi: 10.1001/archderm.1972.01620140005001
- Pasricha JS, Sood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. Br J Dermatol. 1975;93(5):573–576. doi: 10.1111/j.1365-2133.1975.tb02251.x
- Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol. 1978;114(6):889–894. doi: 10.1001/archderm.1978.016401800230057
- Piamphongsant T. Treatment of pemphigus with corticosteroids and cyclophosphamide. J Dermatol. 1979;6(6):359–363. doi: 10.1111/j.1346-8138.1979.tb01927.x
- Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol. 1987;17(3):437–442. doi: 10.1016/s0190-9622(87)70226-6
- Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol. 2003;49(2):276–280. doi: 10.1067/s0190-9622(03)00859-4
- Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882–894. doi: 10.1016/S0140-6736(19)31778-7
- Kridin K, Schmidt E. Epidemiology of pemphigus. JID Innov. 2021;1(1):100004. doi: 10.1016/j.xjidi.2021.100004
- Khaddour HH, Zaher D, Kassem T, Hasan A. Aggressive refractory pemphigus vulgaris that responded to plasmapheresis: a case report. J Med Case Rep. 2020;14(1):109. doi: 10.1186/s13256-020-02421-w
- Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apher Sci. 2003;28(1):13–18. doi: 10.1016/S1473-0502(02)00095-2
Supplementary files
